Clinical Trial Update: Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, antiviral activity, and pharmacokinetics of BI 207127 plus BI 201335 with or without ribavirin over 4 to 40 weeks in chronic hep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 201335
• BI 207127 (BI-207127)
• Ribavirin (ribavirin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2016-02-01